Boehringer Ingelheim receives ad-interim injunctions against four more domestic pharma companies for patent infringement of its anti-diabetes drug Read more
Boehringer Ingelheim enters global licensing agreement to develop and commercialise antibodies from A*STAR for targetted cancer therapies Read more